NCT06459973View on ClinicalTrials.gov

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2030

Conditions
Advanced Solid Tumors
Interventions
DRUG

intravenous (IV) infusion

YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle

Trial Locations (1)

Unknown

RECRUITING

Jilin Provincial Cancer Hospital, Changchun

All Listed Sponsors
lead

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY